Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 81.3%

Neg 0% Neu 0% Pos 81.3%

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.